Prelude Capital Management’s Atara Biotherapeutics ATRA Stock Holding History

Prelude Capital Management’s Portfolio ATRA Stock Details ATRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1,601	Closed	-$631K	–	1808
2021 Q4	$631K	Buy	+1,601	New	+$674K	0.02%	870
2021 Q3	–	Sell	-3,191	Closed	-$1.24M	–	1730
2021 Q2	$1.24M	Sell	3,191 -362	-10%	-$129K	0.04%	503
2021 Q1	$1.28M	Buy	+3,553	New	+$1.57M	0.03%	516
2020 Q4	–	Sell	-4	Closed	-$1K	–	1293
2020 Q3	$1K	Buy	+4	New	+$1.36K	﹤0.01%	1713
2018 Q4	–	Sell	-89	Closed	-$92K	–	1768
2018 Q3	$92K	Buy	+89	New	+$87K	0.01%	977
2017 Q4	–	Sell	-529	Closed	-$219K	–	1355
2017 Q3	$219K	Buy	+529	New	+$199K	0.02%	616

Other funds holding ATRA

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Prelude Capital Management's ATRA Position: Q1 2022 in Review

Prelude Capital Management sold out of Atara Biotherapeutics (ATRA) in Q1 2022, closing a stake of 1,601 shares — an estimated $631K sold.

Prelude Capital Management first reported a position in ATRA in Q3 2017 and held it in 6 quarters. The position peaked at $1.28M in Q1 2021. 144 funds tracked by Wall St. Rank hold ATRA as of Q1 2022.

Prelude Capital Management reported no remaining Atara Biotherapeutics position as of Q1 2022 after selling out during the quarter.
Prelude Capital Management sold 1,601 Atara Biotherapeutics shares in Q1 2022, an estimated $631K.
Prelude Capital Management first reported a position in Atara Biotherapeutics in Q3 2017 and held it in 6 quarters.
Prelude Capital Management's Atara Biotherapeutics position peaked at $1.28M in Q1 2021.
144 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q1 2022.

Based on Prelude Capital Management's 13F filing for Q1 2022, filed 16 May 2022.